RXi Pharmaceuticals gets US patent related to self-delivering technology to treat fibrotic disorders
The patent covers the use of sd-rxRNAs targeting CTGF, including RXI-109, for the treatment of fibrotic disorders. US patent number 8,664,189, will expire in 2029. The notice of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.